MX2022000411A - Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona. - Google Patents

Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona.

Info

Publication number
MX2022000411A
MX2022000411A MX2022000411A MX2022000411A MX2022000411A MX 2022000411 A MX2022000411 A MX 2022000411A MX 2022000411 A MX2022000411 A MX 2022000411A MX 2022000411 A MX2022000411 A MX 2022000411A MX 2022000411 A MX2022000411 A MX 2022000411A
Authority
MX
Mexico
Prior art keywords
compound
self
tetrahydropyrazolopyrimid
pharmaceutical composition
compositions
Prior art date
Application number
MX2022000411A
Other languages
English (en)
Inventor
Raumer Markus Von
Francis Hubler
Mark Murphy
Dorte Renneberg
Simon Stamm
Sylvie Froidevaux
Michael Ambuehl
Elvire Fournier
Amandine Fraichard
Oliver Geiseler
Charlyse Herrmann
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2022000411A publication Critical patent/MX2022000411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas, que son autoemulsificantes, automicroemulsificantes o autonanoemulsificantes en medio acuoso, que comprenden el compuesto: 2-(2,2-difluoro-propil)-5-[1-(2-fluoro-6-metil-fenil)-p iperidin-4-il]-7-(2-trifluorometil-bencil)-2,4,5,7-tetrahidro-pir azolo[3,4-d]pirimidin-6-ona (ver Fórmula) y una mezcla de excipientes que comprende uno o más excipiente(s) lipofílico(s); uno o más tensoactivo(s) hidrofílico(s); y opcionalmente uno o más codisolvente(s) hidrofílico(s). La invención además se refiere a una forma cristalina de dicho compuesto, y su uso para la preparación de las presentes composiciones. La invención además se refiere a usos farmacéuticos de las composiciones para la prevención / profilaxis o el tratamiento de enfermedades y trastornos relacionados con eventos patógenos asociados con niveles elevados de C5a y/o con activación de C5aR.
MX2022000411A 2019-07-09 2020-07-08 Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona. MX2022000411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019068419 2019-07-09
PCT/EP2020/069230 WO2021005101A1 (en) 2019-07-09 2020-07-08 Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound

Publications (1)

Publication Number Publication Date
MX2022000411A true MX2022000411A (es) 2022-02-10

Family

ID=71409436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000411A MX2022000411A (es) 2019-07-09 2020-07-08 Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona.

Country Status (14)

Country Link
US (1) US20220265658A1 (es)
EP (1) EP3996682B1 (es)
JP (1) JP2022540780A (es)
KR (1) KR20220034821A (es)
CN (1) CN114096252A (es)
AU (1) AU2020312183A1 (es)
BR (1) BR112021024038A2 (es)
CA (1) CA3146386A1 (es)
CL (1) CL2022000040A1 (es)
IL (1) IL289619A (es)
MX (1) MX2022000411A (es)
SG (1) SG11202113254PA (es)
TW (1) TW202116323A (es)
WO (1) WO2021005101A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091641A1 (ru) 2018-01-10 2020-11-17 Идорсия Фармасьютиклз Лтд 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2022259205A1 (en) * 2021-06-11 2022-12-15 Universidade Da Beira Interior Self-emulsifying composition, production methods and uses thereof
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308712A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a HIV protease inhibitor
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
EA202091641A1 (ru) * 2018-01-10 2020-11-17 Идорсия Фармасьютиклз Лтд 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ

Also Published As

Publication number Publication date
CN114096252A (zh) 2022-02-25
US20220265658A1 (en) 2022-08-25
WO2021005101A1 (en) 2021-01-14
JP2022540780A (ja) 2022-09-20
SG11202113254PA (en) 2021-12-30
EP3996682A1 (en) 2022-05-18
EP3996682B1 (en) 2024-02-28
EP3996682C0 (en) 2024-02-28
KR20220034821A (ko) 2022-03-18
CL2022000040A1 (es) 2022-11-11
IL289619A (en) 2022-03-01
TW202116323A (zh) 2021-05-01
AU2020312183A1 (en) 2022-01-20
CA3146386A1 (en) 2021-01-14
BR112021024038A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
MX2022000411A (es) Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona.
PH12017502179A1 (en) Substituted heterocyclyl derivatives as cdk inhibitors
WO2004054974A3 (en) Piperidine derivatives as ccr5 antagonists
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
AU2003297048A8 (en) Cyclohexyl compounds as ccr5 antagonists
CR8569A (es) Inhibidores de integrasa de vih
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
CR20220537A (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MX2022013388A (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune.
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2011045068A3 (en) Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2020008360A (es) Forma cristalina de bictegravir sodico.
CN109069466B (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
MX2019008118A (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MY197442A (en) Novel compounds and their use in the treatment of schistosomiasis
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.